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Background : Platelets are closely associated with vascular occlusive event. High on-clopidogrel platelet reactivity (HPR) is associated with recurrent 
thrombotic events after percutaneous coronary intervention (PCI).
Objective : We evaluated platelet reactivity measured by the VerifyNow P2Y12 assay and clinical outcomes in patients receiving clopidogrel and 
percutaneous coronary intervention of real world practice.
methods: We recruited A total of 878 consecutive clopidogrel-treated patients undergoing emergent or elective PCI for stable angina or acute 
coronary syndrome. The main outcome measures were cardiovascular (CV) death, definite/probable stent thrombosis (ST), nonfatal myocardial 
infarction (MI), coronary revacularization and a composite end point of ischemic events. We assessed Platelet reactivity 12 hours later by measuring 
P2Y12 reactivity unit (PRU) with VerifyNow P2Y12 assay (Accumetrics, San Diego, California). HPR was defined as PRU value ≥ 240 or 280.
results: In total, 877 consecutive patients were enrolled. Patients with HPR were 454. In all patients, coronary stent was implanted. VerifyNow 
P2Y12 cartridge was used in 877 patients. All patients received clopidogrel pretreatment (300mg loading dose), received a maintenance dose 
of 75 mg daily. The composite end points of the study at follow-up of 12 months were CV death, nonfatal MI, and coronary revascularization. At a 
12-month follow-up, we found 85 ischemic events (26 CV deaths [3.4%], 11 nonfatal MIs [1.4%]) and 56 target-vessel revascularizations (7.1%). 
The composite event rate of patients with HPR ( PRU > 240 ) was significantly higher ( 7.5% vs 4.3%, p = 0.047 ) than the patient with normal value. 
In survival analysis, there was no significant difference between patient with HPR ( PRU > 240 ) and normal reactivity. But between patient with HPR ( 
PRU > 280 ) and normal reactivity, the survival rate free from the primary end point was significantly lower in patients with HPR ( p = 0.014 ).
Conclusion: High on-clopidogrel platelet reactivity tested by VerifyNow predict coronary adverse event I n patients after PCI. In Korean, we seem to 
have to raise the optimal cutoff value of PRU to predict future coronary event.
